NASDAQ:PRTA

Prothena Stock Forecast, Price & News

$51.01

+2.29 (+4.70 %)

(As of 06/18/2021 12:00 AM ET)

Add

Compare

Today's Range

$48.86

▼

$53.28

50-Day Range

$21.63

▼

$57.65

52-Week Range

$9.39

▼

$59.74

Volume1.13 million shs

Average Volume448,909 shs

Market Capitalization$2.25 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.55

30 days | 90 days | 365 days | Advanced Chart

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

About Prothena

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

Prothena Corp: Why Jeffries Analyst Almost Doubled His Price Target On the Stock? - Yahoo Finance
June 18, 2021 | finance.yahoo.com

Court decision on ACA is a positive on the sector: Bernstein, Prothena upgraded at BofA; in today’s analyst action - Seeking Alpha
June 18, 2021 | seekingalpha.com

Prothena Corp: Why Jeffries Analyst Almost Doubled His Price Target On the Stock? - Nasdaq
June 18, 2021 | nasdaq.com

Prothena Corp: Why Jeffries Analyst Almost Doubled His Price Target On the Stock?
June 18, 2021 | finance.yahoo.com

Prothena (NASDAQ:PRTA) Upgraded to "Neutral" at Bank of America
June 18, 2021 | americanbankingnews.com

Prothena (NASDAQ:PRTA) Upgraded to "Neutral" by Bank of America
June 18, 2021 | americanbankingnews.com

Prothena (NASDAQ:PRTA) Shares Gap Up to $57.65
June 17, 2021 | americanbankingnews.com

Prothena nears a four-year high with a Street high target from Jefferies - Seeking Alpha
June 16, 2021 | seekingalpha.com

Prothena (NASDAQ:PRTA) Trading 2.7% Higher
June 15, 2021 | americanbankingnews.com

Financial Analysis: Immutep (NASDAQ:IMMP) versus Prothena (NASDAQ:PRTA)
June 11, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRTA
Previous Symbol
CUSIPN/A
CIK1559053
Webwww.prothena.com
Phone011-353-1236-2500
Employees66
Year FoundedN/A

Sales & Book Value

Annual Sales$850,000.00
Price / Sales2,651.08
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.61 per share
Price / Book11.07

Profitability

EPS (Most Recent Fiscal Year)($2.78)
Net Income$-111,140,000.00
Net Margins-14,255.73%
Return on Equity-57.65%
Return on Assets-34.35%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares44,176,000
Market Cap$2.25 billion
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.72 out of 5 stars

Medical Sector

274th out of 2,100 stocks

Pharmaceutical Preparations Industry

132nd out of 831 stocks

2.4 Analyst's Opinion

Consensus Rating
Prothena has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.38, Prothena has a forecasted downside of 7.1% from its current price of $51.01.
Amount of Analyst Coverage
Prothena has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.8 Community Rank

Outperform Votes
Prothena has received 564 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Prothena has received 435 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Prothena has received 56.46% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote “Outperform” if you believe PRTA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Prothena does not currently pay a dividend.
Dividend Growth
Prothena does not have a long track record of dividend growth.

3.3 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prothena insiders have bought more of their company's stock than they have sold. Specifically, they have bought $18,156,250.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 30.40% of the stock of Prothena is held by insiders.
Percentage Held by Institutions
90.50% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Prothena are expected to decrease in the coming year, from ($1.67) to ($3.18) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prothena is -16.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prothena is -16.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Prothena has a P/B Ratio of 11.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Prothena (NASDAQ:PRTA) Frequently Asked Questions

Is Prothena a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Prothena stock.
View analyst ratings for Prothena or view top-rated stocks.

What stocks does MarketBeat like better than Prothena?

Wall Street analysts have given Prothena a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Prothena wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Prothena's next earnings date?

Prothena is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Prothena.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) posted its earnings results on Monday, May, 10th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.11. The biotechnology company earned $0.16 million during the quarter, compared to analyst estimates of $0.17 million. Prothena had a negative net margin of 14,255.73% and a negative trailing twelve-month return on equity of 57.65%.
View Prothena's earnings history.

How has Prothena's stock been impacted by COVID-19 (Coronavirus)?

Prothena's stock was trading at $9.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PRTA stock has increased by 424.8% and is now trading at $51.01.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for PRTA?

9 equities research analysts have issued 12 month price objectives for Prothena's shares. Their forecasts range from $29.00 to $62.00. On average, they anticipate Prothena's stock price to reach $47.38 in the next year. This suggests that the stock has a possible downside of 7.1%.
View analysts' price targets for Prothena or view top-rated stocks among Wall Street analysts.

Who are Prothena's key executives?

Prothena's management team includes the following people:

Mr. Gene G. Kinney, Pres, CEO & Director (Age 52, Pay $901.12k)
Mr. Tran B. Nguyen M.B.A., CFO & COO (Age 47, Pay $679.37k)
Mr. Michael J. Malecek, Chief Legal Officer & Company Sec. (Age 55, Pay $588.25k)
Ms. Carol D. Karp, Chief Regulatory Officer (Age 68, Pay $624.39k)
Mr. Brandon S. Smith, Chief Bus. Officer (Age 46, Pay $580.92k)
Ms. Karin L. Walker CPA, Chief Accounting Officer & Controller (Age 58)
Dr. Wagner M. Zago, Chief Scientific Officer (Age 48)
Ms. Jennifer Zibuda, Director of Investor Relations & Communication
Ellen Rose, Head of Communications
Dr. Radhika Tripuraneni M.P.H., M.D., Chief Devel. Officer (Age 41)

Who are some of Prothena's key competitors?

Some companies that are related to Prothena include Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Ultragenyx Pharmaceutical (RARE), Sarepta Therapeutics (SRPT), Biohaven Pharmaceutical (BHVN), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), I-Mab (IMAB), TG Therapeutics (TGTX), Schrödinger (SDGR), Legend Biotech (LEGN) and Reata Pharmaceuticals (RETA).
View all of PRTA's competitors.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include (CGC), Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Who are Prothena's major shareholders?

Prothena's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (8.98%), Price T Rowe Associates Inc. MD (7.50%), First Light Asset Management LLC (6.65%), Redmile Group LLC (4.20%), Palo Alto Investors LP (3.94%) and Dimensional Fund Advisors LP (3.95%). Company insiders that own Prothena stock include Ecor1 Capital, Llc and Wagner M Zago.
View institutional ownership trends for Prothena.

Which major investors are selling Prothena stock?

PRTA stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Prosight Management LP, Dimensional Fund Advisors LP, D. E. Shaw & Co. Inc., Eversept Partners LP, Acadian Asset Management LLC, Morgan Stanley, and BlackRock Inc..
View insider buying and selling activity for Prothena or view top insider-selling stocks.

Which major investors are buying Prothena stock?

PRTA stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Redmile Group LLC, First Light Asset Management LLC, UBS Asset Management Americas Inc., EAM Global Investors LLC, TD Asset Management Inc., EAM Investors LLC, and Palo Alto Investors LP.
View insider buying and selling activity for Prothena or or view top insider-buying stocks.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $51.01.

How much money does Prothena make?

Prothena has a market capitalization of $2.25 billion and generates $850,000.00 in revenue each year. The biotechnology company earns $-111,140,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis.

How many employees does Prothena have?

Prothena employs 66 workers across the globe.

What is Prothena's official website?

The official website for Prothena is www.prothena.com.

Where are Prothena's headquarters?

Prothena is headquartered at 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected]

This page was last updated on 6/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here